Lee Danner & Bass Inc. Takes $48,000 Position in Illumina, Inc. (NASDAQ:ILMN)

Lee Danner & Bass Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 358 shares of the life sciences company’s stock, valued at approximately $48,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $32,000. Versant Capital Management Inc grew its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina in the fourth quarter valued at about $45,000. Assetmark Inc. grew its position in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares in the last quarter. Finally, TD Private Client Wealth LLC grew its position in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on ILMN. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a research report on Friday, February 28th. Citigroup decreased their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Royal Bank of Canada decreased their target price on Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 12th. Finally, Barclays restated an “underweight” rating on shares of Illumina in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and an average price target of $140.90.

Illumina Stock Performance

ILMN stock opened at $87.66 on Friday. The company has a 50 day moving average price of $108.20 and a 200 day moving average price of $128.27. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a fifty-two week low of $80.18 and a fifty-two week high of $156.66. The stock has a market capitalization of $13.89 billion, a PE ratio of -11.41, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.